- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01090245
Using Incentives to Improve Parolee Participation and Attendance in Community Treatment (PIP)
Using Incentives to Improve Parolee Participation and Attendance in Community Tx
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment program to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
A considerable body of research indicates that prison-based treatment followed by continuing treatment in the community is effective in reducing drug abuse and crime among drug-abusing offenders. However, the impact of providing treatment is less than optimal because offenders often fail to follow through on treatment referrals, leave treatment early, or have poor engagement in treatment activities. In particular, participation in prison-based treatment alone is seldom effective in reducing drug use or recidivism unless it is followed by participation in community treatment. For correctional systems that provide a continuum of care model from prison to community, low rates of admission and retention result in poor outcomes and poor resource utilization. One way to address this problem is to provide incentives to parolees for community treatment participation. Although research supports the effectiveness of behavioral reinforcement, mainly in the form of contingency management (CM), for general substance abuse populations, CM has not yet been tested or adapted for use in community-based programs for offender populations, particularly to encourage treatment attendance.
In addition, recent research has documented elevated rates of HIV infection among incarcerated populations compared to the general population, with prevalence of HIV among inmates in US prisons being estimated to be 6 to 10 times higher than in the general population. Upon release from prison, parolees often immediately resume high-risk behaviors that they engaged in prior to incarceration. Because of the high level of exposure to HIV infection that accompanies drug use, particularly by injection, drug treatment programs for high-risk offenders can serve as a valuable setting for preventing the spread of HIV, both through HIV prevention/education activities and through access to HIV testing and counseling.
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- At least 18 years of age
- English speaking
- Within one month of parole
- Able to provide informed consent to participate in the study
- Received a referral to the Walden House Los Angeles Transitional Treatment Center
Exclusion Criteria:
- Potential subjects will be excluded from participating if they have serious cognitive problems that preclude their ability to provide informed consent or understanding of the questionnaire items, if they are a sexually violent predator or a child molester or if they have severe mental health problems.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Attendance Information Group
Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
|
Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
|
|
Experimenteel: Attendance Incentive Group
Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
|
Contingency management: Escalation with reset for non-attendance.
Daily.
Up to $841.50 in incentives for treatment attendance.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Community treatment admission
Tijdsspanne: Within 7 days of release to parole
|
Within 7 days of release to parole
|
|
Community treatment retention
Tijdsspanne: 6 months
|
6 months
|
|
Participation in HIV testing and counseling
Tijdsspanne: 2 months
|
2 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Substance abuse
Tijdsspanne: 18 months after release from prison
|
18 months after release from prison
|
|
|
Arrest and reincarceration
Tijdsspanne: 18 months after release from prison
|
18 months after release from prison
|
|
|
psychosocial: employment, education, family relationships, psychological functioning, and HIV risk
Tijdsspanne: 18 months after release from prison
|
employment, education, family relationships, psychological functioning, and HIV risk
|
18 months after release from prison
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Michael L Prendergast, Ph.D., University of California, Los Angeles
- Studie directeur: Elizabeth A Hall, Ph.D., University of California, Los Angeles
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- middelenmisbruik behandeling
- beheer van onvoorziene omstandigheden
- criminal justice populations
- substance abuse treatment retention
- HIV prevention in criminal justice settings
- voucher based reinforcement therapy
- Parole treatment admission for substance abusing parolees
- Parole treatment retention for substance abusing parolees
- HIV testing and counseling for substance abusing parolees
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1R01DA025627-01A1 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .